AI Engines For more Details: Perplexity Kagi Labs You
Anthelmintic Activity: Avermectin B1a exhibits potent anthelmintic activity against a wide range of parasitic worms, including gastrointestinal nematodes, lungworms, mites, and ticks. It works by disrupting the nervous system of the parasites, leading to paralysis and death.
Broad Spectrum: Avermectin B1a has a broad spectrum of activity against both endoparasites (internal parasites) and ectoparasites (external parasites). It is effective against various species of nematodes, arthropods, and other parasites that affect animals.
Safety in Animals: Avermectin B1a is generally considered safe for use in animals when administered at recommended doses. However, overdoses or misuse can lead to adverse effects, including neurotoxicity, muscle weakness, ataxia (loss of coordination), and potentially fatal respiratory depression.
Drug Resistance: Prolonged or indiscriminate use of avermectin B1a can contribute to the development of drug-resistant parasites. Therefore, it is essential to use anthelmintic medications judiciously and rotate them periodically to minimize the risk of resistance.
Environmental Impact: Avermectin B1a, like other anthelmintic agents, can persist in the environment and may have adverse effects on non-target organisms, including aquatic organisms and insects. Proper disposal and wastewater treatment are necessary to minimize environmental contamination.
Human Health Concerns: While avermectin B1a is considered safe for use in animals, direct exposure to humans should be minimized. Accidental ingestion or contact with the skin or mucous membranes can lead to adverse effects, including irritation, allergic reactions, and neurological symptoms.
Regulatory Considerations: Avermectin B1a is regulated by government agencies responsible for animal health and agriculture. It is important to follow label instructions and adhere to regulations regarding its use, dosage, and withdrawal periods to ensure food safety and minimize the risk of residues in animal products.
Combination Products: Avermectin B1a is often formulated in combination with other anthelmintic agents or drugs to enhance its efficacy or broaden its spectrum of activity. Combination products may provide synergistic effects against parasitic infections but should be used according to label instructions.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 2.8 | 0.3 | 8.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 2.2 | 0.55 |
| Allergies | 4.8 | 2 | 1.4 |
| Allergy to milk products | 1.5 | 1.6 | -0.07 |
| Alopecia (Hair Loss) | 1.3 | 1.3 | |
| Alzheimer's disease | 3.4 | 6 | -0.76 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.6 | 0.8 | 2.25 |
| Ankylosing spondylitis | 4.1 | 1.5 | 1.73 |
| Anorexia Nervosa | 1.6 | 2.6 | -0.63 |
| Antiphospholipid syndrome (APS) | 1.3 | 0.3 | 3.33 |
| Asthma | 4.5 | 1.4 | 2.21 |
| Atherosclerosis | 1.6 | 1.3 | 0.23 |
| Atrial fibrillation | 3.4 | 3.1 | 0.1 |
| Autism | 7.3 | 8.4 | -0.15 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.9 | 1.9 | |
| Bipolar Disorder | 2.1 | 1.1 | 0.91 |
| Brain Trauma | 0.6 | 1.4 | -1.33 |
| Breast Cancer | 0.5 | 0.5 | |
| Cancer (General) | 2.2 | -2.2 | |
| Carcinoma | 3.2 | 2 | 0.6 |
| Celiac Disease | 2 | 3.2 | -0.6 |
| Cerebral Palsy | 1.1 | 1.3 | -0.18 |
| Chronic Fatigue Syndrome | 2.9 | 5.5 | -0.9 |
| Chronic Kidney Disease | 3.7 | 2.6 | 0.42 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.2 | 1.4 | 0.57 |
| Chronic Urticaria (Hives) | 1.5 | 0.9 | 0.67 |
| Coagulation / Micro clot triggering bacteria | 1.8 | 1.3 | 0.38 |
| Cognitive Function | 2.8 | 1.3 | 1.15 |
| Colorectal Cancer | 5.7 | 2.4 | 1.38 |
| Constipation | 1.6 | 0.7 | 1.29 |
| Coronary artery disease | 2.5 | 2.1 | 0.19 |
| COVID-19 | 5.2 | 7.9 | -0.52 |
| Crohn's Disease | 6.3 | 4.6 | 0.37 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 1.1 | 1.3 | -0.18 |
| d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
| deep vein thrombosis | 1.6 | 1.4 | 0.14 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 7.8 | 8.5 | -0.09 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 1.6 | 0.06 |
| Endometriosis | 3.3 | 1.9 | 0.74 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 2.9 | 1.7 | 0.71 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 2.8 | 2 | 0.4 |
| Functional constipation / chronic idiopathic constipation | 5 | 3.9 | 0.28 |
| gallstone disease (gsd) | 3.6 | 0.8 | 3.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 1.2 | -2 |
| Generalized anxiety disorder | 2.7 | 2 | 0.35 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.5 | 0.8 |
| Graves' disease | 1.3 | 2.7 | -1.08 |
| Gulf War Syndrome | 0.9 | 0.5 | 0.8 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 3 | 1.8 | 0.67 |
| Heart Failure | 4.7 | 1.9 | 1.47 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 1.8 | 0.6 | 2 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.7 | |
| hyperglycemia | 1.7 | 1.1 | 0.55 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.4 | 4.3 | 0.02 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 3.4 | 0.3 | 10.33 |
| IgA nephropathy (IgAN) | 1.3 | 2.9 | -1.23 |
| Inflammatory Bowel Disease | 5.7 | 7.5 | -0.32 |
| Insomnia | 2.2 | 2.1 | 0.05 |
| Intelligence | 1.3 | 0.6 | 1.17 |
| Intracranial aneurysms | 1.2 | 0.3 | 3 |
| Irritable Bowel Syndrome | 5.1 | 3.1 | 0.65 |
| ischemic stroke | 2.8 | 1.7 | 0.65 |
| Liver Cirrhosis | 6.2 | 3.5 | 0.77 |
| Long COVID | 3.9 | 5.8 | -0.49 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 1 | -0.11 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 0.5 | 2.1 | -3.2 |
| ME/CFS without IBS | 1.1 | 2.1 | -0.91 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.9 | 0.5 | 0.8 |
| Metabolic Syndrome | 5.6 | 5.4 | 0.04 |
| Mood Disorders | 7.2 | 6.9 | 0.04 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 5.6 | 6.3 | -0.13 |
| Multiple system atrophy (MSA) | 1 | 0.7 | 0.43 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 2.3 | -2.3 | |
| Neuropathy (all types) | 0.4 | 1.6 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.3 | 3.9 | 0.1 |
| NonCeliac Gluten Sensitivity | 0.7 | 0.6 | 0.17 |
| Obesity | 7.8 | 6.2 | 0.26 |
| obsessive-compulsive disorder | 4.3 | 4 | 0.07 |
| Osteoarthritis | 2.1 | 1.2 | 0.75 |
| Osteoporosis | 1.9 | 1.3 | 0.46 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 6.6 | 6.3 | 0.05 |
| Polycystic ovary syndrome | 6.4 | 2.6 | 1.46 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 0.9 | 0.5 | 0.8 |
| Primary sclerosing cholangitis | 1.8 | 3.2 | -0.78 |
| Psoriasis | 2.2 | 3.4 | -0.55 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.7 | 3.2 | 1.09 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 4 | 2.8 | 0.43 |
| scoliosis | 0.7 | 1.2 | -0.71 |
| Sjögren syndrome | 2 | 2 | 0 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.6 | 1.5 |
| Stress / posttraumatic stress disorder | 2.8 | 1.8 | 0.56 |
| Systemic Lupus Erythematosus | 3.4 | 1.7 | 1 |
| Tic Disorder | 0.7 | 1.5 | -1.14 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.8 | 3.3 | -0.18 |
| Type 2 Diabetes | 6 | 4.6 | 0.3 |
| Ulcerative colitis | 4.6 | 4.6 | 0 |
| Unhealthy Ageing | 3.9 | 2.2 | 0.77 |
| Vitiligo | 2.1 | 1.5 | 0.4 |
